Last reviewed · How we verify
Open Label Run In Esomeprazole
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Open Label Run In Esomeprazole |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole. It irreversibly inhibits the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, reducing both basal and stimulated gastric acid production. This mechanism provides rapid and sustained acid suppression, making it effective for treating acid-related gastrointestinal disorders.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Flatulence
Key clinical trials
- Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors (PHASE4)
- A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy (PHASE1, PHASE2)
- Phase 3/Safety & Efficacy of Esomeprazole in Infants (PHASE3)
- Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Open Label Run In Esomeprazole CI brief — competitive landscape report
- Open Label Run In Esomeprazole updates RSS · CI watch RSS
- AstraZeneca portfolio CI